Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third Hospital, Beijing 100083, China, reported in Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):310-3, that fecal calprotectin as a non-invasive screening biomarker in the differential diagnosis of IBS and symptomatic chronic large intestinal organic disease was better than FOBT, ESR and CRP. It was simple, inexpensive, repeatable and no-invasive. It can be used as a biomarker in exclusion from related organic diseases before the diagnosis of irritable bowel syndrome. PMID: 16778979

CALPRO TEAM

  • Anne Thjømøe

    Executive Chairman  Mail: athjomoe@calpro.no Direct line: +47 97 73 37 51 more...

  • Einar Mørk

    Dir. OperationsE-mail: einar@calpro.noDirect line: +47 47 28 55 61 more...

  • Mona Schartum

    Production Manager E-Mail: mona.schartum@calpro.no Direct line: +47 93 22 73 63 more...

  • Ingvild haukø bilde

    Ingvild Haukø

    Sales- and Marketing Manager e-mail: ingvild@calpro.no Direct line: +47 92 01 52 18 more...

  • Ali Qamar

    Product Manager E-mail: ali@calpro.no Direct line: +47 41 17 81 19 more...

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

Latest News

View all latest

Share This